Literature DB >> 3010108

Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications.

P W Gold, D L Loriaux, A Roy, M A Kling, J R Calabrese, C H Kellner, L K Nieman, R M Post, D Pickar, W Gallucci.   

Abstract

Primary depression can be associated with substantial hypercortisolism, thus prompting some researchers to suggest that depression shares pathophysiologic features with Cushing's disease. Clinically, depression can be difficult or impossible to distinguish from mild or early Cushing's disease that is associated with depressive features. The purpose of this study was to evaluate whether the pituitary-adrenal responses to ovine corticotropin-releasing hormone could help to clarify the mechanism of hypercortisolism in depression and in Cushing's disease and to assist in the differential diagnosis of these disorders. As compared with controls (n = 34), depressed patients (n = 30) had basal hypercortisolism (P less than 0.001) that was associated with attenuated plasma ACTH responses to ovine corticotropin-releasing hormone (P less than 0.001). This indicates that in patients with depression, the corticotroph cell in the pituitary responds appropriately to the negative feedback of high cortisol levels. In contrast, patients with Cushing's disease (n = 29) had plasma ACTH hyperresponsiveness to ovine corticotropin-releasing hormone (P less than 0.001), despite basal hypercortisolism (P less than 0.001), which indicates a gross impairment of the mechanism by which cortisol exerts negative feedback on the pituitary. Less than 25 percent of the patients with depression or Cushing's disease had peak ACTH responses that overlapped. We conclude that the pathophysiologic features of hypercortisolism in depression and Cushing's disease are distinct in each of the disorders and that the ovine corticotropin-releasing hormone stimulation test can be helpful in their differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3010108     DOI: 10.1056/NEJM198605223142101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  68 in total

1.  Acute and chronic effects of the atypical antidepressant, mianserin on brain noradrenergic neurons.

Authors:  A L Curtis; R J Valentino
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity.

Authors:  Jing Liu; Ming Guo; Di Zhang; Shao-Ying Cheng; Meilian Liu; Jun Ding; Philipp E Scherer; Feng Liu; Xin-Yun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

Review 3.  Safety and side effects of human and ovine corticotropin-releasing hormone administration in man.

Authors:  M Nink; U Krause; H Lehnert; J Beyer
Journal:  Klin Wochenschr       Date:  1991-03-18

Review 4.  The physiological roles of placental corticotropin releasing hormone in pregnancy and childbirth.

Authors:  Murray Thomson
Journal:  J Physiol Biochem       Date:  2012-12-29       Impact factor: 4.158

5.  Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors.

Authors:  G Cantarella; L Lempereur; G Lombardo; A Chiarenza; C Pafumi; G Zappalà; R Bernardini
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Expression of the mouse corticotropin-releasing hormone gene in vivo and targeted inactivation in embryonic stem cells.

Authors:  L J Muglia; N A Jenkins; D J Gilbert; N G Copeland; J A Majzoub
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 7.  The organization of the stress system and its dysregulation in depressive illness.

Authors:  P W Gold
Journal:  Mol Psychiatry       Date:  2014-12-09       Impact factor: 15.992

8.  Regulation of corticosteroid receptor gene expression in depression and antidepressant action.

Authors:  N Barden
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

Review 9.  Benzodiazepines and anterior pituitary function.

Authors:  E Arvat; R Giordano; S Grottoli; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

Review 10.  Hypothalamic-pituitary-adrenocortical axis dysfunction in epilepsy.

Authors:  Aynara C Wulsin; Matia B Solomon; Michael D Privitera; Steve C Danzer; James P Herman
Journal:  Physiol Behav       Date:  2016-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.